Consort Medical has announced that its Bespak subsidiary has entered into a multi-year agreement to supply its proprietary integrated dose counter system and the valve for a commercial pMDI. This is the first commercial use of the Bespak integrated dose counter (IDC) in an orally inhaled MDI; the IDC is already used in Teva’s QNASL beclomethasone HFA nasal aerosol, which was approved in 2012. The new device will be manufactured at Bespak’s King’s Lynn, UK facility.
Consort Medical CEO Jonathan Glenn commented, “Consort Medical has a long heritage of excellence, reliability and innovation and we strive to be the partner of choice for pharmaceutical companies, enabling them to implement drug delivery technologies that can streamline and accelerate the route to market for their drugs. With the conclusion of this agreement for our IDC device we have reinforced the ongoing strength of our respiratory device franchise, in particular in the pMDI segment, and created a significant business opportunity.”
Read the Consort Medical press release.
